Which Bone-Modifying Agents Are Most Effective in Reducing Bone Loss in Women with Early and Locally Advanced Breast Cancer?-A Cochrane Review summary with commentary
Journal of Musculoskeletal Neuronal Interactions, cilt.24, sa.4, ss.332-335, 2024 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 24 Sayı: 4
- Basım Tarihi: 2024
- Doi Numarası: 10.1002/14651858.cd013451.pub2
- Dergi Adı: Journal of Musculoskeletal Neuronal Interactions
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, MEDLINE
- Sayfa Sayıları: ss.332-335
- Anahtar Kelimeler: Bisphosphonate, Bone Loss, Breast Cancer, Denosumab, Quality of Life
- İstanbul Üniversitesi Adresli: Evet
Özet
The aim of this commentary is to discuss from a rehabilitation perspective the Cochrane Review “Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis”[1] by Adams et al.a, published by the Cochrane Breast Cancer Group. This Cochrane Corner is produced in agreement with Journal of Musculoskeletal and Neuronal Interactions by Cochrane Rehabilitation with views* of the review summary author in the “implications for practice” section.